RCS - IXICO plc - Conference attendance and presentations

IXICOAnnouncement

01/03/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210301:nRSA5972Qa&default-theme=true

RNS Number : 5972Q  IXICO plc  01 March 2021

 

IXICO plc

("IXICO" or the "Company")

 

Conference attendance and presentations

IXICO virtually attends AD/PD 2021 Conference

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in
neuroscience, announces it will be presenting at the upcoming virtual AD/PD
2021 conference taking place virtually on 9-14 March 2021. AD/PD 2021, the
15th International Conference on Alzheimer's and Parkinson's Diseases and
related neurological disorders, is one of the most prestigious in the year and
IXICO welcomes the opportunity to present.

 

The following presentation and poster presentations will be made across the
week:

 

·    Michael Reinwald, PhD, Associate Research Engineer at IXICO plc, will
give a pre-recorded oral presentation, titled: "A deep-learning based
framework for brain-atrophy measurement"

 

·    Jack Weatheritt, PhD, Senior Research Engineer at IXICO plc, will
present the poster: "Automatic segmentation using deep learning for the
hippocampus"

 

·    Luis Peraza, PhD, Research Engineer at IXICO plc, will present two
posters:

1) "An adaptive step detection algorithm for waist-worn wearable devices: a
feasibility study in older adults"

2) "Added value of wearable sensors for fall risk assessment in an older adult
group"

 

The conference attracts international medical and scientific professionals
worldwide to focus on the mechanisms of disease, prevention and therapy within
the neurodegenerative disease space. More information on the conference can be
found here: Welcome Message - AD/PD™ 2021 | March 9 - 14, 2021 | Virtual
Conference (kenes.com) (https://adpd.kenes.com/welcome-message/)

 

Robin Wolz, Chief Scientific Officer at IXICO, commented: "We are excited
about the opportunity to provide an update on various R&D activities at
the AD/PD conference. Deep learning approaches in combination with well
curated, high-quality data enable us to develop tools that can extract
clinically meaningful insights that were previously not detectable and at a
processing speed previously unthinkable. We look forward to sharing an update
on how this technology impacts our ability to interpret both imaging and
wearables data."

 

The video presentation and related posters will be available on the Company's
website after the event has concluded, here: Webinars » IXICO
(https://ixico.com/news-and-resources/webinars/) and Publications » IXICO
(https://ixico.com/news-and-resources/publications/) .

 

 

For further information please contact:

 

 IXICO plc                                                    +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                       +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd      +44 (0)20 7933 8780
 Paul McManus / Lianne Cawthorne /         IXICO@walbrookpr.com (mailto:IXICO@walbrookpr.com)
 Alice Woodings

 

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to
advance medicine and human health by turning data into clinically meaningful
information, providing valuable new insights in neuroscience and our goal is
to be a leading proponent of artificial intelligence in medical image
analysis. We will achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform, to improve
the return on investment in drug development and reduce risk and uncertainty
in clinical trials for our pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on Twitter @IxicOplc

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUPGPUPGURM